Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.47 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28784050 | 0.90 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAPOLBITGB3ITGA2B | |
| SCHEMBL686783 | 0.90 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAPOLBITGB3ITGA2B | |
| SCHEMBL9829245 | 0.88 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAPOLBITGB3ITGA2B | |
| SCHEMBL14701528 | 0.87 | ALDH1A1 (0.59) | SMN1; SMN2LMNAPOLBALDH1A1HTT | |
| SCHEMBL14535420 | 0.87 | ALDH1A1 (0.59) | SMN1; SMN2LMNAPOLBALDH1A1HTT | |
| SCHEMBL6859171 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2LMNAPOLBITGB3ITGA2B | |
| SCHEMBL6857598 | 0.86 | KEAP1 (0.59) | SMN1; SMN2LMNAPOLBITGB3ITGA2B | |
| SCHEMBL14224491 | 0.86 | RIPK1 (0.62) | SMN1; SMN2LMNAPOLBALDH1A1HTT | |
| SCHEMBL14224547 | 0.86 | RIPK1 (0.62) | SMN1; SMN2LMNAPOLBALDH1A1HTT | |
| SCHEMBL9829985 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2ITGB3ITGA2BALDH1A1ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669538-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2020-06-02 | — | — | US | disclosed |
| US-20170198283-A1 | TEMPLATED MOLECULES AND METHODS FOR USING SUCH MOLECULES | NUEVOLUTION A/S (DK) | 2017-07-13 | — | — | US | disclosed |
| US-9688980-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION (DK) | 2017-06-27 | — | — | US | disclosed |
| EP-2534138-B1 | 1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2017-01-25 | — | — | EP | disclosed |
| EP-2305808-B1 | Templated molecules and methods for using such molecules | NUEVOLUTION AS (DK) | 2016-03-02 | — | — | EP | disclosed |
| US-8932992-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2015-01-13 | — | — | US | disclosed |
| US-8809338-B2 | 1,2,3-triazole-based peptidomimetic integrin inhibitors for the diagnosis and therapy of tumors | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2014-08-19 | — | — | US | disclosed |
| WO-2011098603-A1 | 1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2011-08-18 | — | — | WO | disclosed |
| CN-1928102-B | Resolution method of beta-amino acid | ASTATECH CHENGDU PHARMACEUTIACL CO LTD | 2011-08-10 | — | — | CN | disclosed |
| US-7727713-B2 | Templated molecules and methods for using such molecules | NUEVOLUTION A/S (DK) | 2010-06-01 | — | — | US | disclosed |
| CN-1928102-A | Resolution method of beta-amino acid | ASTATECH CHENGDU PHARMACEUTIAC (CN) | 2007-03-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669538-B2 | Templated molecules and methods for using such molecules | ABL1, DHFR, TYMS | SMN1; SMN2 3782/4885LMNA 2667/4885POLB 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.